Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Protalix BioTherapeutics

DB:PBD
Snowflake Description

Weak fundamentals or lack of information.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PBD
DB
$33M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel and internationally. The last earnings update was 24 days ago. More info.


Add to Portfolio Compare Print
  • Protalix BioTherapeutics has significant price volatility in the past 3 months.
PBD Share Price and Events
7 Day Returns
-7.4%
DB:PBD
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
-44.9%
DB:PBD
-13.2%
DE Biotechs
-20.9%
DE Market
PBD Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Protalix BioTherapeutics (PBD) -7.4% -32.4% -47.6% -44.9% -82.5% -89.2%
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • PBD underperformed the Biotechs industry which returned -13.2% over the past year.
  • PBD underperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
PBD
Industry
5yr Volatility vs Market

Value

 Is Protalix BioTherapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Protalix BioTherapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Protalix BioTherapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Protalix BioTherapeutics. This is due to cash flow or dividend data being unavailable. The share price is €2.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Protalix BioTherapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Protalix BioTherapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:PBD PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.23
AMEX:PLX Share Price ** AMEX (2020-04-03) in USD $2.22
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Protalix BioTherapeutics.

DB:PBD PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AMEX:PLX Share Price ÷ EPS (both in USD)

= 2.22 ÷ -1.23

-1.8x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Protalix BioTherapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Protalix BioTherapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Protalix BioTherapeutics's expected growth come at a high price?
Raw Data
DB:PBD PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.8x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Protalix BioTherapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Protalix BioTherapeutics's assets?
Raw Data
DB:PBD PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $-4.74
AMEX:PLX Share Price * AMEX (2020-04-03) in USD $2.22
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:PBD PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AMEX:PLX Share Price ÷ Book Value per Share (both in USD)

= 2.22 ÷ -4.74

-0.47x

* Primary Listing of Protalix BioTherapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Protalix BioTherapeutics has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.

Next steps:

  1. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Protalix BioTherapeutics's regulatory filings and announcements.
  2. Show me more potentially undervalued companies in the Biotechs industry
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Protalix BioTherapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Protalix BioTherapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Protalix BioTherapeutics expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
55.2%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Protalix BioTherapeutics expected to grow at an attractive rate?
  • Unable to compare Protalix BioTherapeutics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Protalix BioTherapeutics's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Protalix BioTherapeutics's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:PBD Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:PBD Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:PBD Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 73
2023-12-31 36
2022-12-31 61
2021-12-31 81
2020-12-31 41 -35 -27 1
2020-04-05
DB:PBD Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 55 -19 -18
2019-09-30 47 -20 -24
2019-06-30 45 -3 -26
2019-03-31 38 -6 -26
2018-12-31 34 -8 -26
2018-09-30 28 14 -34
2018-06-30 23 -10 -40
2018-03-31 25 -11 -32
2017-12-31 21 -10 -83
2017-09-30 19 -35 -73
2017-06-30 16 -28 -69
2017-03-31 11 -31 -80

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Protalix BioTherapeutics is high growth as no earnings estimate data is available.
  • Unable to determine if Protalix BioTherapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:PBD Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Protalix BioTherapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:PBD Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31 -1.14 -1.14 -1.14 1.00
2020-04-05
DB:PBD Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.23
2019-09-30 -1.62
2019-06-30 -1.74
2019-03-31 -1.79
2018-12-31 -1.80
2018-09-30 -2.37
2018-06-30 -2.87
2018-03-31 -2.31
2017-12-31 -6.37
2017-09-30 -5.93
2017-06-30 -5.99
2017-03-31 -7.42

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Protalix BioTherapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Protalix BioTherapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Protalix BioTherapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Protalix BioTherapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Protalix BioTherapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Protalix BioTherapeutics does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Protalix BioTherapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Protalix BioTherapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Protalix BioTherapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Protalix BioTherapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:PBD Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 54.69 -18.28 9.90 44.62
2019-09-30 47.29 -24.00 9.84 43.81
2019-06-30 45.37 -25.76 11.34 43.88
2019-03-31 37.97 -26.48 11.43 37.80
2018-12-31 34.24 -26.46 10.92 33.33
2018-09-30 28.19 -34.33 12.86 31.97
2018-06-30 23.38 -40.44 11.61 28.29
2018-03-31 24.90 -31.53 12.27 29.87
2017-12-31 21.08 -83.44 11.53 28.83
2017-09-30 18.85 -72.76 12.33 24.55
2017-06-30 16.00 -68.61 11.51 23.22
2017-03-31 11.41 -79.80 10.90 22.21
2016-12-31 9.20 -29.18 10.36 23.61
2016-09-30 7.12 -35.12 8.51 24.31
2016-06-30 3.78 -33.85 8.66 23.20
2016-03-31 3.35 -29.30 8.45 20.08
2015-12-31 4.36 -27.28 8.28 19.03
2015-09-30 -5.89 -30.54 8.97 17.66
2015-06-30 -3.52 -32.53 8.82 19.82
2015-03-31 -2.17 -32.47 8.38 20.09
2014-12-31 3.52 -33.30 10.23 21.22
2014-09-30 14.90 -32.36 9.61 24.53
2014-06-30 14.55 -30.10 9.38 24.06
2014-03-31 14.93 -30.81 9.99 25.56
2013-12-31 -34.74 9.18 24.88
2013-09-30 10.44 -26.78 8.48 24.05
2013-06-30 12.47 -26.51 8.92 24.77

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Protalix BioTherapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Protalix BioTherapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Protalix BioTherapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Protalix BioTherapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Protalix BioTherapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Protalix BioTherapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Protalix BioTherapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Protalix BioTherapeutics's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Protalix BioTherapeutics's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Protalix BioTherapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Protalix BioTherapeutics has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Protalix BioTherapeutics Company Filings, last reported 3 months ago.

DB:PBD Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 -70.32 55.26 17.79
2019-09-30 -70.85 55.54 21.44
2019-06-30 -67.49 54.75 25.10
2019-03-31 -59.86 53.96 30.36
2018-12-31 -52.88 52.27 37.81
2018-09-30 -47.94 53.47 41.87
2018-06-30 -42.74 52.00 28.33
2018-03-31 -35.44 57.21 41.32
2017-12-31 -29.46 56.49 51.16
2017-09-30 -26.07 63.84 33.48
2017-06-30 -20.67 57.88 34.53
2017-03-31 -68.47 117.51 48.02
2016-12-31 -9.96 77.52 63.28
2016-09-30 -15.10 72.43 51.32
2016-06-30 -7.98 72.32 54.63
2016-03-31 2.65 72.21 66.67
2015-12-31 10.87 72.10 76.37
2015-09-30 -68.51 67.77 34.25
2015-06-30 -65.14 67.67 43.24
2015-03-31 -61.15 67.57 47.96
2014-12-31 -55.60 67.35 54.77
2014-09-30 -47.69 67.36 60.32
2014-06-30 -39.79 67.26 71.14
2014-03-31 -33.58 67.15 77.69
2013-12-31 -26.95 67.05 86.40
2013-09-30 -16.71 66.94 91.40
2013-06-30 -11.99 0.00 33.13
  • Protalix BioTherapeutics has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Protalix BioTherapeutics's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Protalix BioTherapeutics has less than a year of cash runway based on current free cash flow.
  • Protalix BioTherapeutics has less than a year of cash runway if free cash flow continues to reduce at historical rates of -18.4% each year.
X
Financial health checks
We assess Protalix BioTherapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Protalix BioTherapeutics has a total score of 0/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Protalix BioTherapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Protalix BioTherapeutics dividends.
If you bought €2,000 of Protalix BioTherapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Protalix BioTherapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Protalix BioTherapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:PBD Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:PBD Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-05

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Protalix BioTherapeutics has not reported any payouts.
  • Unable to verify if Protalix BioTherapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Protalix BioTherapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Protalix BioTherapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Protalix BioTherapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Protalix BioTherapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Protalix BioTherapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Protalix BioTherapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Dror Bashan
TENURE AS CEO 0.8 years
CEO Bio

Mr. Dror Bashan has been President, Chief Executive Officer and Director of Protalix BioTherapeutics, Inc. since June 30, 2019, Mr. Bashan has over 20 years of experience in the pharmaceutical industry with roles ranging from business development, marketing, sales and finance providing him with both cross regional and cross discipline experience and a deep knowledge of the global pharmaceutical and health industries. From 1998 through 2018, he served in a number of senior positions at Teva Pharmaceutical Industries Ltd. He served as Teva’s Senior Vice President, Global Business Development, and was involved in strategic alliances, cross-company strategic projects and the acquisition and divestiture of assets. Mr. Bashan holds a BA in Economics and Business Management from the Tel Aviv University in Tel Aviv, Israel, and an MBA from the Tel-Aviv University.

CEO Compensation
  • Insufficient data for Dror to compare compensation growth.
  • Insufficient data for Dror to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Protalix BioTherapeutics management team in years:

5.7
Average Tenure
57
Average Age
  • The average tenure for the Protalix BioTherapeutics management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Yoseph Shaaltiel

TITLE
Founder and Executive VP Research & Development
COMPENSATION
$433K
AGE
65
TENURE
13.3 yrs

Yaron Naos

TITLE
Senior Vice President of Operations
COMPENSATION
$339K
AGE
55
TENURE
1.9 yrs

Einat Brill-Almon

TITLE
Senior Vice President of Product Development
COMPENSATION
$504K
AGE
59
TENURE
13.3 yrs

Dror Bashan

TITLE
President
TENURE
0.8 yrs

Eyal Rubin

TITLE
SVP, CFO & Corporate Secretary
AGE
43
TENURE
0.6 yrs

Dafna Shelly

TITLE
Vice President of Human Resources
TENURE
9.4 yrs
Board of Directors Tenure

Average tenure and age of the Protalix BioTherapeutics board of directors in years:

2.8
Average Tenure
72
Average Age
  • The average tenure for the Protalix BioTherapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Zeev Bronfeld

TITLE
Independent Chairman
COMPENSATION
$80K
AGE
68
TENURE
0.7 yrs

Dror Bashan

TITLE
President
TENURE
0.8 yrs

Roger Kornberg

TITLE
Chairman of Scientific Advisory Board
COMPENSATION
$55K
AGE
72

Amos Shalev

TITLE
Independent Director
COMPENSATION
$80K
AGE
66
TENURE
11.8 yrs

J. Ciechanover

TITLE
Member of Scientific Advisory Board
AGE
72
TENURE
12.7 yrs

Aaron Schwartz

TITLE
Independent Director
COMPENSATION
$66K
AGE
76
TENURE
5.4 yrs

Alexander Levitzki

TITLE
Member of Scientific Advisory Board
AGE
79

Charles Arntzen

TITLE
Member of Scientific Advisory Board
AGE
78
TENURE
3.8 yrs

David Granot

TITLE
Independent Director
COMPENSATION
$20K
AGE
72
TENURE
1.7 yrs

Gwen Melincoff

TITLE
Director
AGE
67
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Protalix BioTherapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Protalix BioTherapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; OPRX-106, an orally-delivered protein product candidate for the treatment of inflammatory bowel disease, as well as completed Phase IIa clinical trial for ulcerative colitis patients; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; and PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. was founded in 1993 and is headquartered in Karmiel, Israel.

Details
Name: Protalix BioTherapeutics, Inc.
PBD
Exchange: DB
Founded: 1993
$30,532,857
14,838,213
Website: http://www.protalix.com
Address: Protalix BioTherapeutics, Inc.
2 Snunit Street,
Science Park,
Karmiel,
2161401,
Israel
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AMEX PLX Ordinary Shares NYSE MKT LLC US USD 03. Jan 2007
DB PBD Ordinary Shares Deutsche Boerse AG DE EUR 03. Jan 2007
TASE PLX Ordinary Shares The Tel-Aviv Stock Exchange IL ILS 03. Jan 2007
Number of employees
Current staff
Staff numbers
196
Protalix BioTherapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/05 21:56
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/03/13
Last earnings filing: 2020/03/12
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.